BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 35855850)

  • 1. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal TACC3 Expression is an Independent Prognostic Biomarker in Lung Carcinoma.
    Zhang X; Fan X; Li X; Wang Y; Zhang Y; Li Y; Zhao J; He D
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):252. PubMed ID: 36042187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
    Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
    PeerJ; 2023; 11():e16166. PubMed ID: 37790630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
    Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer.
    Jiang F; Kuang B; Que Y; Lin Z; Yuan L; Xiao W; Peng R; Zhang X; Zhang X
    Oncol Rep; 2016 Jan; 35(1):436-46. PubMed ID: 26531241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
    Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
    BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
    Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
    Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of the association between tumor-infiltrating immune cells and the prognosis of lung adenocarcinoma.
    Pan Y; Sha Y; Wang H; Zhuang H; Ren X; Zhu X; Wei X
    J Cancer Res Ther; 2020; 16(2):320-326. PubMed ID: 32474519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
    Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
    BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
    Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
    Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.
    Li S; Li H; Cao Y; Geng H; Ren F; Li K; Dai C; Li N
    Medicine (Baltimore); 2021 Aug; 100(32):e26474. PubMed ID: 34397869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
    Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
    Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Wang Y; Wen H; Sun D
    Ann Transl Med; 2022 May; 10(9):519. PubMed ID: 35928739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
    Cao K; Ling X; Jiang X; Ma J; Zhu J
    Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.